Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
| Revenue (TTM) | $136.07M |
| Gross Profit (TTM) | $129.89M |
| EBITDA | $40.55M |
| Operating Margin | 42.30% |
| Return on Equity | 34.80% |
| Return on Assets | 8.74% |
| Revenue/Share (TTM) | $2.37 |
| Book Value | $3.48 |
| Price-to-Book | 3.09 |
| Price-to-Sales (TTM) | 5.03 |
| EV/Revenue | 3.327 |
| EV/EBITDA | 5.92 |
| Quarterly Earnings Growth (YoY) | -88.40% |
| Quarterly Revenue Growth (YoY) | 53.30% |
| Shares Outstanding | $59.38M |
| Float | $53.86M |
| % Insiders | 1.28% |
| % Institutions | 76.83% |
Volatility is currently contracting
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Zevra Therapeutics NASDAQ: ZVRA reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA.
Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2 million Company to host conference call and webcast TODAY, August 5, 2026 , at 4:30 p.m. ET BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today reported its financial results for the second quarter ended June 30, 2026.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 11:00 a.m. ET. Additionally, management will be available for one-on-one meetings with registered conference attendees.
Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the July 24, 2026 negative opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP"). NEW YORK, Aug. 3, 2026 /PRNewswire/ -- On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approximately 24% after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease type C.
Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population
Zevra Therapeutics investors saw shares fall after European regulators issued a negative opinion on arimoclomol. The investigation focuses on Zevra's regulatory statements and the July 24, 2026 CHMP decision. Zevra Therapeutics investors saw shares fall after European regulators issued a negative opinion on arimoclomol. The investigation focuses on Zevra's regulatory statements and the July 24, 2026 CHMP decision.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ZVRA and any ticker you trade — then tracks every position and per-strategy win rate.
